EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐Term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta‐Blocker and Flecainide Therapy

Fernando Wangüemert-Perez, German Ostos-Cañero, Marta Wangüemert-Guerra, Carlos Acosta-Materan, Aridane Cárdenes-León, Eduardo Caballero-Dorta, Kevin Pérez-Rodríguez, Ramón Brugada, Josep Brugada, Efrén Martínez-Quintana iD

Journal of Cardiovascular Electrophysiology · 30.06.2026

DOI: 10.1111/jce.70429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 30.06.2026. Verfasst von Fernando Wangüemert-Perez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiavant, Centro Médico Cardiológico, Las Palmas de Gran Canaria, Spain. Hauptthemen laut MEDLINE: Flecainide, Tachycardia, Ventricular, Exercise Test, Adrenergic beta-Antagonists. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundación Canaria UMIAYA for the care of sudden death.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially life‐threatening arrhythmic disorder typically treated with beta‐blockers and, occasionally, with flecainide.

Methods

All patients underwent genetic testing, electrocardiogram, echocardiogram, and exercise testing. Ventricular arrhythmias were assessed using qualitative and quantitative scoring systems. Flecainide dosing was progressively titrated, and follow‐up extended from 2007 to 2024.

Results

Among 235 genetically confirmed carriers of the RyR2 (ryanodine receptor 2) p.Gly357Ser mutation, 32 required combination therapy with beta‐blockers and flecainide (age at diagnosis 18 [1–55] years; age at flecainide initiation 32 [15–66] years; 50% male). Forty‐seven percent had an implantable cardioverter defibrillator (ICD). Flecainide was indicated for exercise‐induced ventricular arrhythmias despite beta‐blocker therapy, and the median treatment duration was 7.3 years. All patients received propranolol (median dose 65 mg/day). Flecainide (median dose 100 mg/day) was well tolerated, with no syncope or stress‐induced symptoms. Before flecainide, five patients (16%) experienced ventricular arrhythmic events recorded by the ICD, including two requiring appropriate shocks; no events occurred after treatment initiation. Both qualitative (2.07 ± 0.77 vs. 1.22 ± 1.08, p < 0.001) and quantitative (69.78 ± 83.17 vs. 15.29 ± 5.53, p < 0.001) arrhythmic scores improved significantly. Additionally, maximum heart rate and the percentage of age‐predicted maximum heart rate were significantly reduced, while metabolic equivalents increased significantly (12.3 ± 3.8 vs. 14.7 ± 7.5; p = 0.010).

Conclusion

In CPVT patients, the addition of flecainide to beta‐blocker therapy was associated with a significant reduction in arrhythmic burden and improvement in exercise‐related parameters during long‐term follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlecainideTachycardia, VentricularExercise TestAdrenergic beta-AntagonistsAnti-Arrhythmia AgentsHeart RatePropranololHumansPolymorphic Catecholaminergic Ventricular TachycardiaMiddle AgedTreatment OutcomeTime FactorsFemaleAdultMaleAdolescentYoung AdultRyanodine Receptor Calcium Release ChannelChildAgedChild, PreschoolPredictive Value of TestsDrug Therapy, CombinationMutation

Stichwörter der Autor:innen

beta‐blockerscatecholaminergic polymorphic ventricular tachycardia (CPVT)exercise capacityflecainidetreadmill ergometry

Substanzen

FlecainideAdrenergic beta-AntagonistsAnti-Arrhythmia AgentsRyanodine Receptor Calcium Release ChannelRyR2 protein, humanPropranolol

Autor:innen und Institutionen

  • Cardiavant, Centro Médico Cardiológico, Las Palmas de Gran Canaria, Spain.
  • Cardiology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
  • Faculty of Health Sciences, Department of Medical and Surgical Sciences, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
  • Cardiology Service, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.
  • Cardiovascular Genetics Center, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain.
  • Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

ORCID-Profile: Efrén Martínez-Quintana

Förderung

  • Fundación Canaria UMIAYA for the care of sudden death

Zitieren

APA

Wangüemert-Perez, F., Ostos-Cañero, G., Wangüemert-Guerra, M., Acosta-Materan, C., Cárdenes-León, A., Caballero-Dorta, E., Pérez-Rodríguez, K., Brugada, R., Brugada, J., & Martínez-Quintana, E. (2026). Long‐Term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta‐Blocker and Flecainide Therapy. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70429

Vancouver

Wangüemert-Perez F, Ostos-Cañero G, Wangüemert-Guerra M, Acosta-Materan C, Cárdenes-León A, Caballero-Dorta E, et al. Long‐Term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta‐Blocker and Flecainide Therapy. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70429

BibTeX
@article{WangemertPerez2026,
  author = {Wangüemert-Perez, Fernando and Ostos-Cañero, German and Wangüemert-Guerra, Marta and Acosta-Materan, Carlos and Cárdenes-León, Aridane and Caballero-Dorta, Eduardo and Pérez-Rodríguez, Kevin and Brugada, Ramón and Brugada, Josep and Martínez-Quintana, Efrén},
  title = {Long‐Term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta‐Blocker and Flecainide Therapy},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  doi = {10.1111/jce.70429}
}
Kostenlos starten →